Tecemotide
A MUC1 peptide vaccine for lung cancer
Tecemotide is a liposomal vaccine built on the core peptide of MUC1, a glycoprotein that cancers overexpress and abnormally glycosylate. It aims to train T cells to attack tumour cells. In the phase 3 START trial in stage III lung cancer, it did not significantly improve overall survival, though patients who had received concurrent chemoradiotherapy lived ten months longer.
Used in human trials: 806 µg lipopeptide (after cyclophosphamide 300 mg/m² once), Weekly, Injection (route not stated in the abstract) (Trial: START, primary phase) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
MUC1 is a cell-membrane glycoprotein found on breast, lung and other epithelial tissues. In cancer it becomes overexpressed and aberrantly glycosylated, exposing its core peptide repeats to the immune system. Tecemotide packages that peptide in a liposome; in preclinical studies it induced T-cell proliferation in response to MUC1 and interferon-gamma production.
A phase 2 trial in advanced non-small-cell lung cancer found median survival 4.2 months longer with tecemotide plus best supportive care (17.2 against 13.0 months, not significant) and a higher three-year survival rate (31% against 17%). The phase 3 START trial then randomised 1,513 patients with stage III disease after chemoradiotherapy. Median overall survival was 25.6 months against 22.3 months on placebo, not statistically significant (hazard ratio 0.88). In the 65% who had received concurrent chemoradiotherapy, survival was 30.8 against 20.6 months.
Later trials did not rescue it: a Japanese trial found identical survival, and after liver-metastasis surgery it did no better than placebo. Other trials have been modest too: in early breast cancer it did not improve pathological response, and in multiple myeloma it induced a MUC1 immune response in 47% of patients without conventional clinical responses. It has not been approved.
A small phase 2 trial combining it with bevacizumab after chemoradiotherapy reported median survival of 42.7 months in the selected patients who reached treatment; fewer than half of those enrolled got that far, and one died of an oesophageal perforation attributed to bevacizumab. The large confirmatory trial in Asian patients, INSPIRE, was designed with a similar regimen.
The regimen was similar across trials: a single dose of cyclophosphamide (300 mg/m² in START), then weekly injections for 8 weeks and maintenance every 6 weeks; INSPIRE specified subcutaneous injection. In mice, the vaccine needed that cyclophosphamide pretreatment and at least two cycles to shrink tumours, and it combined additively with cisplatin and with letrozole.
Mechanism of Action
Tecemotide is a liposomal vaccine carrying a MUC1 core peptide, designed to train T cells against the aberrant MUC1 on cancer cells.
MUC1 target
Cancer cells overexpress MUC1 with abnormal glycosylation, exposing the peptide repeats the vaccine contains.
T-cell response
It induced MUC1-specific T-cell proliferation and interferon-gamma, and a Th1 response in mice.
Cyclophosphamide priming
Trials gave one dose of cyclophosphamide first; in mice the vaccine worked only with that pretreatment.
Published Research
Studies of tecemotide, from their PubMed abstracts.
START phase 3 in stage III lung cancer
Among 1,239 analysed patients, median overall survival was 25.6 months with tecemotide and 22.3 with placebo (HR 0.88, p = 0.123); after concurrent chemoradiotherapy it was 30.8 against 20.6 months (HR 0.78, p = 0.016), with no difference after sequential chemoradiotherapy.
Phase 2 survival update
Median survival was 17.2 months with L-BLP25 plus best supportive care against 13.0 months with supportive care alone (HR 0.745, not significant); three-year survival was 31% against 17% (P = 0.035).
Early breast cancer
Adding tecemotide to neoadjuvant therapy did not change residual cancer burden (36.4% vs 31.9%, p = 0.40) or complete response (22.5% vs 17.4%), and did not increase toxicity.
Multiple myeloma
In 34 patients, tecemotide induced or augmented a MUC1-specific immune response in 47%, with on-treatment slowing of M-protein rise in 45% of evaluable patients but no conventional clinical responses.
START: updated survival
With about 20 more months of follow-up in stage III lung cancer, median survival was 25.8 months on tecemotide against 22.4 on placebo (hazard ratio 0.89, not significant); in the subgroup given concurrent chemoradiotherapy it was 29.4 against 20.8 months, an exploratory finding.
Japan: no survival gain
In 172 Japanese patients with unresectable stage III non-small-cell lung cancer randomised 2:1 after chemoradiotherapy, median survival was 32.4 months on tecemotide and 32.2 on placebo (hazard ratio 0.95), with similar adverse-event rates.
LICC: after liver-metastasis surgery
In 121 patients whose colorectal liver metastases had been removed, tecemotide did not improve recurrence-free survival (median 6.1 against 11.4 months on placebo) or 3-year survival (69.1% against 79.1%), and MUC1 expression did not predict outcome.
With bevacizumab after chemoradiotherapy
In a cooperative-group phase 2 trial, 33 of 70 patients reached tecemotide plus bevacizumab after chemoradiotherapy; among the 32 treated, median survival was 42.7 months, with one fatal oesophageal perforation attributed to bevacizumab.
INSPIRE design in Asian patients
The INSPIRE phase 3 protocol in East Asian patients with stage III lung cancer used a single cyclophosphamide infusion, then 8 weekly subcutaneous vaccinations of 930 µg and 6-weekly maintenance.
LICC design in colorectal cancer
The LICC protocol after resection of colorectal liver metastases gave cyclophosphamide, then tecemotide with maintenance doses every 6 weeks in years 1 and 2 and every 12 weeks in year 3, with recurrence-free survival as the primary endpoint.
How tecemotide works
Tecemotide was designed to target tumour-associated MUC1, which becomes overexpressed and aberrantly glycosylated in cancer, exposing immunogenic tandem repeats in its extracellular domain.
A human MUC1 mouse model
In transgenic mice carrying human MUC1, L-BLP25 reduced lung tumour foci only with at least two cycles and cyclophosphamide pretreatment, and induced Th1 cytokines.
With cisplatin in mice
In the same mouse model, cisplatin with tecemotide reduced lung tumour foci additively and preserved interferon-gamma responses to the vaccine.
With letrozole in mice
In MUC1-expressing mammary tumours in mice, hormonal therapy did not blunt the vaccine's Th1 response, and L-BLP25 plus letrozole had additive antitumour activity.
Dosing Data
Never approved. Trials gave cyclophosphamide once, then weekly tecemotide injections for 8 weeks and every 6 weeks after.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Tecemotide is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
An arithmetic example, not a recommendation: a 5 mg vial mixed with 2 mL of bacteriostatic water holds 2,500 mcg per mL, so every 10 units on a U-100 insulin syringe hold 250 mcg. 806 µg, the first amount in the “Trial: START, maintenance” row (806 µg lipopeptide) is 32.2 units (0.322 mL). If your vial or water differ, the numbers change: use the reconstitution calculator.
Source: dose: Used in human trials, PMID 24331154 (Dosing Data below); vial and water: the calculator's default example, not a vial size we have a source for.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Tecemotide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Tecemotide stays intact once mixed.
How it is taken
As it was given in human studies: Injection (route not stated in the abstract) (Weekly; Trial: START, primary phase).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: START, primary phase: 8 weeks; Trial: START, maintenance: Until progression or withdrawal.
When effects appear: unknown; no source on this page gives a time to effect for Tecemotide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: No added toxicity in the breast cancer trial. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Tecemotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Tecemotide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Tecemotide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (Not approved anywhere). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No label; it is investigational.
Legal Status
Tecemotide is investigational.
Frequently Asked Questions
?What is tecemotide?
An investigational liposomal vaccine built on the core peptide of MUC1, designed to make the immune system attack cancer cells that overexpress it.
?Did tecemotide work in lung cancer?
Not overall: in the phase 3 START trial median survival was 25.6 against 22.3 months, not significant, although patients who had received concurrent chemoradiotherapy lived 30.8 against 20.6 months.
?Was it tested in other cancers?
Yes, in early breast cancer, where it did not improve response to neoadjuvant therapy, and in multiple myeloma, where it induced immune responses without conventional clinical responses.
?Why did the trial results depend on earlier treatment?
In START, patients who had received chemotherapy and radiotherapy at the same time lived longer with tecemotide (30.8 against 20.6 months), while those treated sequentially saw no difference. A subgroup finding like this needs confirming in a new trial before it can guide treatment.
?Why were some patients excluded from the main analysis?
Of 1,513 randomised patients, 274 were excluded from the primary analysis because of a clinical hold during the trial, leaving 829 on tecemotide and 410 on placebo.
?Why was cyclophosphamide given first?
Trials gave one dose before vaccination (300 mg/m² in START); in mouse studies the vaccine reduced tumours only after cyclophosphamide pretreatment and at least two cycles.
?Was tecemotide combined with other drugs?
In a phase 2 trial after chemoradiotherapy it was given with bevacizumab; among 32 treated patients median survival was 42.7 months, with one fatal oesophageal perforation attributed to bevacizumab. In mice it combined additively with cisplatin and letrozole.
References
- [clinical-trial] Butts C, et al. "Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial." Lancet Oncol, 2014;15(1):59-68. PMID: 24331154.
- [clinical-trial] Butts C, et al. "Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial." J Cancer Res Clin Oncol, 2011;137(9):1337-42. PMID: 21744082.
- [clinical-trial] Singer CF, et al. "Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)." Eur J Cancer, 2020;132:43-52. PMID: 32325419.
- [clinical-trial] Rossmann E, et al. "Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study." Hum Vaccin Immunother, 2014;10(11):3394-408. PMID: 25483677.
- [pubmed] Wurz GT, et al. "Tecemotide: an antigen-specific cancer immunotherapy." Hum Vaccin Immunother, 2014;10(11):3383-93. PMID: 25483673.
- [clinical-trial] Mitchell P, et al. "Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses." Ann Oncol, 2015;26(6):1134-1142. PMID: 25722382.
- [clinical-trial] Katakami N, et al. "Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer." Lung Cancer, 2017;105:23-30. PMID: 28236981.
- [clinical-trial] Schimanski CC, et al. "Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)." Oncoimmunology, 2020;9(1):1806680. PMID: 32923171.
- [pubmed] Patel JD, et al. "Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)." Clin Lung Cancer, 2020;21(6):520-526. PMID: 32807654.
- [pubmed] Wu YL, et al. "INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer." BMC Cancer, 2011;11:430. PMID: 21982342.
- [pubmed] Schimanski CC, et al. "LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial." BMC Cancer, 2012;12:144. PMID: 22494623.
- [pubmed] Wurz GT, et al. "Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model." J Transl Med, 2013;11:64. PMID: 23496860.
- [pubmed] Kao CJ, et al. "Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model." Cancer Immunol Res, 2014;2(6):581-9. PMID: 24894093.
- [pubmed] Mehta NR, et al. "L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice." Clin Cancer Res, 2012;18(10):2861-71. PMID: 22434666.
Sources & Citations
Studies were read from their PubMed abstracts. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.